Navigation Links
Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs
Date:3/18/2008

HAYWARD, Calif., March 18 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) today announced that the company will reduce its workforce by approximately 37% in order to focus resources on supporting advancement of its lead clinical programs, tanespimycin in multiple myeloma and in metastatic breast cancer, and epothilone KOS-1584 in non-small lung cancer. The restructuring will primarily affect the company's research and administrative functions. As a result of the restructuring, most research programs will be placed on hold. The company may seek to partner these assets with companies looking for early-stage programs.

"Restructuring our workforce to focus resources on development of our lead clinical programs completes the strategic reprioritization of Kosan's development portfolio that we recently announced. This represents an important step in Kosan's evolution to a product-oriented company," said Helen S. Kim, Kosan's Chief Executive Officer. "We appreciate the efforts of all our employees as their contributions have helped to build our company's reputation as a leader in polyketide technology as well as Hsp90 and epothilone drug discovery. We believe that this restructuring will strengthen our ability to effectively manage our resources, execute on our development goals and advance our high-value, near-term commercial opportunities."

Kosan anticipates incurring restructuring charges of approximately $0.7 million in the first quarter of 2008, primarily associated with personnel-related termination costs. As a result of the restructuring, Kosan is reducing its 2008 guidance for cash used in operating activities by $3.0 million, from $40-$50 million to $37-$47 million.

About Kosan

Kosan Bi
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Kosans Board of Directors Appoints Helen S. Kim as Chief Executive Officer
2. Kosan Biosciences to Present at the Cowen and Company 28th Annual Health Care Conference
3. Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference
4. Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
5. Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
6. Kosan Announces February 28, 2008 Conference Call and Webcast
7. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
8. Kosan Announces Third Quarter 2007 Financial Results
9. Kosan to Reacquire Epothilone Program From Roche
10. Kosan Biosciences to Host Research & Development Day on October 31, 2007
11. Kosan Biosciences to Present at the Biotechnology Industry Organization Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 23, 2014 Follow us ... steady popularity the world over, due to its ... in the marketplace is expected to come from ... developing countries. Several sub-Saharan countries in the African ... already implemented genetically engineered crop production strategies. Rising ...
(Date:9/23/2014)... Sept. 23, 2014 News Facts ... India devoted to genome-based research for human health ... is taking a bite out of oral cancer with ... in India with the help of ... DataDirect Networks (DDN). , To fuel its cutting-edge cancer ...
(Date:9/23/2014)... 2014 Cambridge Semantics, the leading provider ... was named in the recent ‘Hype Cycle for Life ... The report details key insights pertaining to the benefits ... Gartner analysts Michael Shanler and Stephen Davies, “The use ... complex relationships with scientific stakeholders, and support collaboration and ...
(Date:9/23/2014)... Texas Fertility Center (TFC) announces the ... expanding a Central Texas footprint that includes Round Rock, ... office for the region’s most established practice will provide ... Austin, Buda, Kyle and San Marcos communities. , ... directly to individuals and couples living in and around ...
Breaking Biology Technology:Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 4National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 2National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 3National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 4National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 5Cambridge Semantics Identified in Gartner’s ‘Hype Cycle for Life Sciences 2014’ Report 2Opening Doors to a Family: Texas Fertility Center Announces Newest Fertility Clinic in South Austin 2Opening Doors to a Family: Texas Fertility Center Announces Newest Fertility Clinic in South Austin 3
... XIANYANG, China, May 17 /PRNewswire-Asia-FirstCall/ -- ... a Xianyang-,based manufacturer of a leading over-the-counter Hepatitis B medicine, ... pharmaceutical,products, today announced financial results of the first quarter ended ... Q1 2010 revenue increased 66.0% to $12.4 million, ...
... May 16 Astellas Pharma Inc. (TSE: 4503), ... ), a biotechnology company primarily focused on the discovery, development and ... and obesity, today announced that they have entered into a definitive ... , , ...
... AutoImmune Inc. (Pink Sheets: AIMM) today announced that ... dissolution pursuant to a Plan of Complete Liquidation and Dissolution ... 11, 2010 .  Stockholders voted overwhelmingly in favor of the ... Liquidation and Dissolution, with the proposal receiving an affirmative vote ...
Cached Biology Technology:Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 2Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 3Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 4Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 5Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 6Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 7Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 8Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 9Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 10Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 11Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 12Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 13Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc. 2Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc. 3Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc. 4Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc. 5Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc. 6
(Date:9/22/2014)... the University of Chicago have shown that after a ... a handful of pathogenic microbe species remain behind in ... discovered that some can become deadly when provoked by ... , The findings, published in mBio , the ... may lead to better monitoring and treatment of ICU ...
(Date:9/22/2014)... Yale University researchers are studying a potential new treatment ... disease in which scars develop in the lungs and ... mimic, miR-29, which is delivered to lung tissue intravenously. ... it reversed fibrosis after several days. , The ... EMBO Molecular Medicine . , "The mimic, when injected ...
(Date:9/22/2014)... Rochelle, NY, September 22, 2014Cassava, also known as tapioca, ... yields in areas of Africa, Asia, and Latin America ... the availability of novel enzymes and processes designed to ... be used to produce sweeteners such as glucose, fructose, ... to corn, as described in a Review article in ...
Breaking Biology News(10 mins):Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 2Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 3Reversing the effects of pulmonary fibrosis 2
... of the 2010 Science in Society Journalism Awards, sponsored by ... In the Book category, Susan Cohen and Christine ... and the Medical Industry,s Quest to Manipulate Height" (Tarcher/Penguin). ... from the Associated Press and the New York Times. Martha ...
... first time in more than ten years, there has been a ... in the world, the saola of Laos and Vietnam. The ... announced on September15 that in late August villagers in the central ... their village. The animal died several days later, but was ...
... Inc., (AOptix) ( www.aoptix.com ), a leading-edge developer ... optical communications solutions, today announced that AOptix and ... be demonstrating a prototype dual-factor iris and face ... the upcoming Biometrics Consortium Conference and Technology Expo. ...
Cached Biology News:Science in Society Journalism Award winners announced 2Science in Society Journalism Award winners announced 3Asian 'unicorn' photographed for first time in over 10 years 2Asian 'unicorn' photographed for first time in over 10 years 3AOptix Technologies to Show Combined Biometric Face and Iris Capture System at Biometrics Consortium Conference 2AOptix Technologies to Show Combined Biometric Face and Iris Capture System at Biometrics Consortium Conference 3
... MBP Coated Microplate, 96 Well Anti-phospho-MBP, ... Magnesium/ATP Cocktail, #20-11 Blocking Buffer, 10X, ... LumiGLO™ Chemiluminescen Applications: ... Routinely evalauted by non-radioactive ...
Zebrafish Ephrin-B2 Biotinylated Affinity Purified PAb...
... ActivePro In Vitro Translation ... E.coli lysate, synthesizes higher ... well as proteins with ... competing kits. This results ...
...
Biology Products: